TREAT-TO-TARGET IN RHEUMATOID ARTHRITIS:
CLINICAL AND PHARMACOECONOMIC CONSIDERATIONS

Target Audience
Rheumatologists

Course Description
The proposed supplement to the journal *Clinical and Experimental Rheumatology* is the 13th in an annual series entitled *Contemporary Topics in Rheumatic Diseases*. The series presents articles written by thought leaders in the field, for wide distribution to rheumatologists as well as internists and family practitioners. The 2012 supplement will address the topic “Treat-to-Target in Rheumatoid Arthritis: Clinical and Pharmacoeconomic Considerations,” with 28 proposed articles, each focusing on a specific aspect of treatment. “Treat-to-target” is currently the standard of care for rheumatoid arthritis (RA), the most common rheumatic disease, with early, aggressive treatment using weekly low-dose methotrexate, low-dose prednisone, and biological agents in patients with incomplete responses to methotrexate. However, many rheumatologists have not adopted “treat-to-target” in their clinical care. There are a number of reasons for this, including: complexity of quantitative measurement of RA, requiring indices; lack of familiarity of rheumatologists with RA indices; complexities of the therapies, with requirements for additional testing such as PPD for use of biological agents; and high costs of biological therapies, requiring prior approvals and complex administrative strategies.

Statement of Need
In order to implement a “treat-to-target” strategy in patients with rheumatoid arthritis (RA), it is necessary to be familiar with quantitative indices to provide the target, which is a largely unmet need in the rheumatology community. The superior efficacy of biological agents in incomplete responders to methotrexate has been demonstrated, but most rheumatologists do not use these agents in all patients in whom they would be indicated according to a “treat-to-target” strategy, in part because of high costs and administrative complexity.

Educational Objectives
- Incorporate quantitative indices, including the DAS28, CDAI and/or RAPID3 to assess patients with RA, and recognize moderate or high activity, for a ‘treat-to-target’ strategy toward low activity or remission.
- Formulate treatment plans for the use of biological therapies with knowledge of pharmacoeconomic considerations of cost vs. benefit ratio when seeking prior approval of biological agents.

Accreditation Statement
The NYU Post-Graduate Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The NYU Post-Graduate Medical School designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
To receive up to 10 CME credits, read this supplement, which should take 10 hours of your time, complete the evaluation and post-test and submit to the NYU Post-Graduate Medical School (instructions enclosed). A minimum passing grade of 70% is required.

This activity is valid for credit from December 1, 2012 through February 28, 2013.

Faculty Credentials
Ariel Beresniak, MD, MPH, PhD
Interdisciplinary Laboratory of Applied Research in Health Economics
Paris-Descartes University
Paris, France

Prof. Dr. Jürgen Braun
Professor of Rheumatology
Ruhr University Bochum
Herne, Germany

Paolo Cortesi, PharmD, PhD
Research Centre on Public Health
University of Milano – Bicocca
Milan, Italy

Prof. Gianfranco Ferraccioli
Professor of Rheumatology
School of Medicine of the Catholic University of the Sacred Heart
Rome, Italy

Merete Lund Hetland, MD, PhD, DMSc
Associate Professor and Consultant in Rheumatology
Copenhagen University, Faculty of Health Sciences and Glostrup Hospital
Copenhagen, Denmark

Johannes WG Jacobs, MD, PhD
Associate Professor of Rheumatology
University Medical Center Utrecht
Utrecht, The Netherlands
Disclosure Statement
The NYU Post-Graduate Medical School adheres to ACCME Essential Areas and policies, including the Standards for Commercial Support, regarding industry support of continuing medical education. In order to resolve any identified conflicts of interest, disclosure information is provided during the planning process to ensure resolution of any identified conflicts. Disclosure of faculty and commercial relationships as well as the discussion of unlabeled or unapproved use of any drug, device or procedure by the faculty is listed below.

Ariel Beresniak, MD, MPH, PhD – Author reports no relevant financial relationships.

Prof. Dr. Jürgen Braun – Author reports no relevant financial relationships.

Paolo Cortesi, PharmD, PhD – Author reports no relevant financial relationships.

Prof. Gianfranco Ferraccioli – Author reports no relevant financial relationships.

Merete Lund Hetland, MD, PhD, DMSc – Author reports no relevant financial relationships.

Johannes WG Jacobs, MD, PhD – Author reports no relevant financial relationships.

Arthur Kavanaugh, MD – Author reports no relevant financial relationships.

Raashid Luqmani, DM – Author reports no relevant financial relationships. Dr Luqmani’s article will include discussion of the unlabelled or unapproved use of a drug, device or procedure; i.e. cyclophosphamide in vasculitis.

Marta Mosca, MD, PhD – Author reports no relevant financial relationships.

Theodore Pincus, MD – Planner and Author serves as a consultant to Genentech, Inc., Janssen Biotech, and UCB, Inc. and serves on the speakers’ bureau of Bristol-Myers Squibb, Genentech, Inc., and Merck and Co. He is the recipient of research funding from Bristol-Myers Squibb.

Duncan Porter, MD – Author reports no relevant financial relationships.

Vappu Rantalaiho, MD, PhD – Author reports no relevant financial relationships.

Angelo Ravelli, MD – Author reports no relevant financial relationships.

Josef Smolen, MD – Author reports no relevant financial relationships.

David L. Scott, BSc, MD – Author serves as a consultant to Merck Sharp & Dohme, Ltd. and Bristol-Myers Squibb. He serves on the speakers’ bureau of Thompson Reuters and UCB Pharma.

Marianne van den Broek, MD
Leiden University Medical Center
Leiden, The Netherlands

Yusuf Yazici, MD
Assistant Professor of Medicine
NYU School of Medicine
New York, NY